Nanovibronix (FEED) versus Its Competitors Critical Survey

Nanovibronix (NASDAQ:FEED) is one of 28 public companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it weigh in compared to its competitors? We will compare Nanovibronix to similar companies based on the strength of its dividends, valuation, earnings, analyst recommendations, risk, profitability and institutional ownership.

Institutional & Insider Ownership

16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by institutional investors. 1.4% of Nanovibronix shares are held by company insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Nanovibronix and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-275.12%	-24.78%	-19.24%
Nanovibronix Competitors	-672.41%	-133.75%	-59.01%

Analyst Recommendations

This is a summary of current ratings and target prices for Nanovibronix and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1	0	0	0	1.00
Nanovibronix Competitors	77	76	156	6	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 51.09%. Given Nanovibronix’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Nanovibronix has less favorable growth aspects than its competitors.

Risk and Volatility

Nanovibronix has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500. Comparatively, Nanovibronix’s competitors have a beta of 1.76, meaning that their average stock price is 76% more volatile than the S&P 500.

Valuation & Earnings

This table compares Nanovibronix and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Nanovibronix	$2.56 million	-$3.70 million	-0.07
Nanovibronix Competitors	$58.84 million	-$32.15 million	4.18

Nanovibronix’s competitors have higher revenue, but lower earnings than Nanovibronix. Nanovibronix is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Nanovibronix competitors beat Nanovibronix on 7 of the 12 factors compared.

Nanovibronix Company Profile

NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.